title: [Fever and neutropenia in children with cancer: a new therapeutic proposal].
abstract: Based on our previous experience treating children with cancer, fever and neutropenia we selected two different empirical regimens: Ceftriaxone once a day, for patients with solid tumors and lymphomas I-II (Low Risk group--LR) and Imipenem for patients with leukemias and lymphomas III-IV (High Risk group--HR). From Oct 1988 to Nov 1989, 121 episodes of fever (F+) and granulocytopenia (G+) in LR Group and 119 in HR Group were studied: the HR had 51.3% documented infections and the LR 58.7%. In the HR Group the following organisms were isolated from the blood cultures: Gram + 52%, Gram - 20% and fungal 28%. In the LR Group 78% of the organisms were Gram+. Positive blood cultures was 21% for the HR Group and 8.3% for the LR Group. There were 23.5% superinfections in the HR Group vs 5.7% in the LR. The mean time and the median time of granulocytopenia was 11.5 and 8 days (HR) and 6.9 and 6.0 days (LR), respectively. There were 14.5% (LR) and 45.4% (HR) modifications to the initial empirical antibiotic regimen (Amphotericin B, Vancomycin and Amikacin). The overall success rate was 97.6% (LR) and 94.2% (HR) and for documented infection the success rate was 95.7% (LR) and 91.8% (HR). We conclude that: a) The allocation of patients to two risk groups aiming to use distinguished therapy, allowed us to delineate two different populations, predominantly based on time of granulocytopenia, disappearance of fever, rate of superinfection, causative organisms and need of additional drugs to the initial scheme.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Dep. de Oncol. Pediát. do Hosp. A.C. Camargo.
authors.forename: A S
authors.initials: AS
authors.lastname: Petrilli
authors.forename: R
authors.initials: R
authors.lastname: Melaragno
authors.forename: A
authors.initials: A
authors.lastname: Bianchi
authors.forename: E
authors.initials: E
authors.lastname: Kusano
authors.forename: K V
authors.initials: KV
authors.lastname: Barros
authors.forename: A A
authors.initials: AA
authors.lastname: Silva
mesh_terms: D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D001938:Brazil; D002443:Ceftriaxone / Q000627:therapeutic use*; D002648:Child; D005334:Fever / Q000150:complications / Q000188:drug therapy*; D005658:Fungi / Q000302:isolation & purification; D006090:Gram-Negative Bacteria / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*
chemical_list: D015378:Imipenem; D002443:Ceftriaxone
vernacular_title: Febre e neutropenia em crianças com câncer: nova proposta terapêutica.